Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Spyre (SYRE) PT Raised to $107 at Stifel

May 5, 2026 4:26 PM EDT

Stifel analyst Alex Thompson raised the price target on Spyre (NASDAQ: SYRE) to $107.00 (from $92.00) while maintaining a Buy rating.

The analyst comments "Following best-in-class UC PoC data for SPY001 (a4B7), SYRE is well-positioned heading into additional PoC cohorts for... More